Mankind Pharma Q3 FY26 Unaudited Results: Consolidated Revenue ₹3,567 Cr, PAT ₹414 Cr
Mankind Pharma reported Q3 FY26 consolidated revenue of ₹3,567.20 crore and profit after tax of ₹413.88 crore. Standalone revenue was ₹2,632.68 crore with profit after tax of ₹449.47 crore. The Board approved the results on February 3, 2026.
The results show a year-on-year increase in revenue and profit, which is material information for investors. However, there was a sequential dip in consolidated revenue and profit, which tempers the impact to medium.
The company reported positive financial results with revenue and profit growth compared to the same quarter last year, indicating a stable business performance.
Mankind Pharma Limited has announced its unaudited financial results for the quarter and nine months ended December 31, 2025. The company reported consolidated revenue from operations of ₹3,567.20 crore for the quarter, a slight decrease from ₹3,697.16 crore in the previous quarter but an increase from ₹3,198.79 crore in the same quarter last year.
Consolidated profit after exceptional items and tax for the quarter stood at ₹413.88 crore, compared to ₹520.18 crore in the previous quarter and ₹377.87 crore in the corresponding quarter of the previous year. Total comprehensive income for the quarter was ₹419.83 crore.
For the nine months ended December 31, 2025, consolidated revenue from operations was ₹10,834.71 crore. Profit after exceptional items and tax for the nine-month period was ₹1,378.68 crore, and total comprehensive income was ₹1,406.78 crore.
The company also provided standalone financial information. For the quarter ended December 31, 2025, standalone revenue from operations was ₹2,632.68 crore. Standalone profit after exceptional items and tax was ₹449.47 crore, with total comprehensive income at ₹452.53 crore.
For the nine months ended December 31, 2025, standalone revenue from operations was ₹7,839.36 crore. Standalone profit after exceptional items and tax was ₹1,329.04 crore, and total comprehensive income was ₹1,349.21 crore.
The Board of Directors approved these unaudited consolidated and standalone financial results at their meeting held on February 3, 2026. The full financial results are available on the stock exchanges' websites and the company's website.
What to do with a filing like this
Mankind Pharma Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Mankind Pharma Limited. Read the original for the full detail.